684,116 Shares in AMNEAL PHARMACEUTICALS, INC. $AMRX Bought by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC recently acquired a $5.73 million stake in Amneal Pharmaceuticals, purchasing 684,116 shares, which amounted to approximately 0.22% of the company's total stock.
• Multiple institutional investors, including Janney Montgomery Scott LLC and Allspring Global Investments, have increased their positions in Amneal Pharmaceuticals substantially during the first quarter.
• Amneal Pharmaceuticals has received a consensus rating of "Buy" from analysts, with an average target price of $11.60, despite recent downgrades from a "strong-buy" rating.

Cubist Systematic Strategies LLC purchased a new position in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 684,116 shares of the company's stock, valued at approximately $5,733,000. Cubist Systematic Strategies LLC owned about 0.22% of AMNEAL PHARMACEUTICALS at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in AMRX. Hsbc Holdings PLC grew its holdings in AMNEAL PHARMACEUTICALS by 29.7% during the fourth quarter. Hsbc Holdings PLC now owns 60,061 shares of the company's stock worth $476,000 after purchasing an additional 13,757 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of AMNEAL PHARMACEUTICALS by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 97,250 shares of the company's stock worth $771,000 after acquiring an additional 9,704 shares during the last quarter. Northern Trust Corp raised its position in AMNEAL PHARMACEUTICALS by 9.7% in the 4th quarter. Northern Trust Corp now owns 1,777,283 shares of the company's stock worth $14,076,000 after purchasing an additional 156,699 shares during the period. BNP Paribas Financial Markets boosted its stake in AMNEAL PHARMACEUTICALS by 209.2% during the fourth quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after acquiring an additional 113,796 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of AMNEAL PHARMACEUTICALS by 218.8% during the fourth quarter. Bank of America Corp DE now owns 556,881 shares of the company's stock valued at $4,410,000 after purchasing an additional 382,222 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Insider Activity

In related news, EVP Nikita Shah sold 114,492 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $9.66, for a total value of $1,105,992.72. Following the sale, the executive vice president owned 152,743 shares of the company's stock, valued at $1,475,497.38. The trade was a 42.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the transaction, the executive vice president owned 10,606 shares in the company, valued at $95,984.30. This represents a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 609,206 shares of company stock worth $5,700,625 in the last 90 days. Insiders own 17.45% of the company's stock.

Analyst Ratings Changes

AMRX has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on shares of AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $11.60.

AMNEAL PHARMACEUTICALS Price Performance

NASDAQ AMRX traded down $0.05 during trading hours on Tuesday, hitting $9.69. The company had a trading volume of 322,034 shares, compared to its average volume of 1,664,079. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of 969.47 and a beta of 1.19. AMNEAL PHARMACEUTICALS, INC. has a fifty-two week low of $6.68 and a fifty-two week high of $9.80. The firm's 50 day moving average is $8.71 and its 200 day moving average is $8.14.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. On average, equities analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current year.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.